A detailed history of Seven Mile Advisory transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Seven Mile Advisory holds 642 shares of VRTX stock, worth $320,922. This represents 0.22% of its overall portfolio holdings.

Number of Shares
642
Previous 609 5.42%
Holding current value
$320,922
Previous $255 Million 18.21%
% of portfolio
0.22%
Previous 0.19%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$392.81 - $485.53 $12,962 - $16,022
33 Added 5.42%
642 $301 Million
Q1 2024

May 08, 2024

BUY
$407.69 - $446.08 $2,038 - $2,230
5 Added 0.83%
609 $255 Million
Q4 2023

Feb 09, 2024

SELL
$343.0 - $410.68 $343 - $410
-1 Reduced 0.17%
604 $246 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $2,367 - $2,537
7 Added 1.17%
605 $210 Million
Q2 2023

Aug 08, 2023

BUY
$314.42 - $351.91 $188,023 - $210,442
598 New
598 $210 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $128B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Seven Mile Advisory Portfolio

Follow Seven Mile Advisory and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Mile Advisory, based on Form 13F filings with the SEC.

News

Stay updated on Seven Mile Advisory with notifications on news.